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Summary 
Vaccination of mice with heat shock protein  70 (hsp70) preparations  derived from the Meth 
A  sarcoma, but not from normal  tissues, renders the mice immune  to a substantial challenge 
with Meth A  sarcoma. The immunogenicity is dose dependent and tumor specific.  Treatment 
of an antigenically active hsp70 preparation with ATP followed by removal of low-molecular 
weight material leaves hsp70 intact,  as judged by SDS-PAGE but results in loss of antigenicity, 
as judged by tumor rejection assays. Separation of this low-molecular weight material on a C18 
reverse-phase column shows a diverse array of peptides with molecular mass between 1,000 and 
5,000 daltons. Our data indicate that antigenicity of hsp70 preparations derives, not from hsp70 
per se, but from associated peptides. These observations may suggest a novel method of using 
the peptide-binding property of hsp70 for specific vaccination against cancer and infectious diseases. 
I 
mmune response to heat shock proteins (HSP)  1 has been 
the focus of considerable attention (1). There are three major 
paradigms  of this response:  one, where HSP are processed 
and presented like other antigens by MHC class I or II mole- 
cules and recognized by c~//3 T  cells (2-4);  second, where 
3r//~ T  cells recognize HSP by a poorly understood mecha- 
nism (5, 6); and third, where an immune response to an HSP 
leads to autoimmunity because of cross-reactivity between 
the HSP and a non-HSP self-antigen (7, 8). A  new fourth 
paradigm of immune response to HSP, in which immuniza- 
tion with an HSP elicits immunity not against the HSP it- 
self, but against antigenic peptides chaperoned by the HSP, 
has emerged. The prototype of this fourth paradigm is the 
HSP gp96.  It has been demonstrated that mice or rats im- 
munized with gp96 preparations from a given tumor develop 
immunological resistance to the tumor from which gp96 is 
isolated,  but  not  to  antigenically  distinct  tumors  (9-12, 
Janetzki,  S.,  N.  E.  Blachere,  and P. K.  Srivastava,  unpub- 
lished results), gp96 preparations isolated from normal tissues 
do not elicit resistance to any tumors tested (13).  Examina- 
tion of the structural basis of the immunological specificity 
of gp96 from normal tissues and tumors has suggested that 
gp96 molecules are not immunogenic per se, but are carriers 
(chaperones) of antigenic peptides (14-16). Heat-shock pro- 
tein 90 (hsp90), the cytosolic counterpart of gp96, has also 
been shown to elicit tumor-specific immunity  against  the 
1 Abbreviations used in this  paper: HSP, heat-shock protein; hsp70 and 90, 
heat-shock protein 70 and 90, respectively;  Meth A, methylcholanthrene 
induced. 
tumors from which it is isolated, but not to antigenically 
distinct tumors (17); in this case, too, the antigenicity does 
not appear to reside in the hsp90 itself (18). 
In this article, we extend this paradigm to one of the most 
extensively studied HSP, hsp70, and demonstrate that hsp70 
preparations  isolated  from  a  methylcholanthrene-induced 
BALB/c fibrosarcoma, Meth A, but not from normal tissues, 
elicit tumor-specific immunity. This immunity appears to be 
elicited, not by the hsp70 molecules themselves, but by the 
ATP-dissociable peptides associated with  hsp70. 
Materials and Methods 
Mice and Antibodies.  BALB/cJ  mice (viral antigen  free) were 
obtained from The Jackson Laboratory (Bar Harbor, ME) and were 
maintained in the virus-free mouse facilities at Mount Sinai School 
of Medicine. Antibodies to hsp70 (anti-HSP72/73,  SPA-820, done 
N27F3-4) were purchased from StressGen Biotechnologies Corp. 
(Victoria, BC, Canada). 
Purification  of  hsp70.  A  40-ml  Meth  A  cell  pellet  was 
homogenized in 120 ml hypotonic buffer (30 mM NaHCO3, 0.5 
mM PMSF, pH 7.1) and a 100,000-g supernatant  obtained.  This 
was applied to a Con A-Sepharose column in presence of 2 mM 
Ca  z+ and 2 mM Mg  ~  +; the Con A unbound material was dialyzed 
against 10 mM "Iris acetate, pH 7.5, 10 mM NaCI,  and 0.1 mM 
EDTA. This fraction was resolved on an FPLC system (Mono O~ 
Pharmacia Inc., Piscataway, NJ) equilibrated with 20 mM Tris ace- 
tate, pH 7.5, 20 mM NaC1, 0.1 mM EDTA, and 15 mM 2-ME. 
The proteins were duted by a 20-500-raM NaCI gradient.  Frac- 
tions (1 ml) were collected, tested by SDS-PAGE, and immuno- 
blotted with a group anti-hsp70 mAb N27F3-4 (StressGen Biotech- 
nologies Corp.). The hsp70-containing fractions were pooled and 
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fate. hsp70 was precipitated at 50-70% ammonium sulfate satura- 
tion. The later fractions in this process were homogeneous by silver 
staining and were used for immunization  of mice. (For purification 
of hsp70 from liver and spleen, the 100,000-g supernatant was first 
applied to a blue Sepharose column to remove albumin.) 
Isolation and A nalysis  of  Peptides  Associated  with hsp  70.  A purified 
hsp70 preparation was centrifuged through an assembly (Centricon 
10, Amicon Corp., Danvers, MA), to remove any low-molecular 
weight material loosely associated with it. The large-molecular 
weight fraction was recovered  and analyzed by SDS-PAGE, whereas 
the low-molecular weight material was analyzed by HPLC, as de- 
scribed later. The hsp70 preparation  was incubated with ATP at 
a final concentration  of 10 mM at room temperature  for 30 min 
and centrifuged  through  Centricon  10 as before. The two frac- 
tions were recovered  and the ATP treatment was repeated two more 
times. The high-molecular  weight fraction was analyzed by SDS- 
PAGE; the lower molecular weight fractions were pooled, concen- 
trated by evaporation in Speed Vac (Savant Instruments,  Inc., Far- 
mingdale,  NY), and dissolved in 0.1%  TFA.  This  material was 
applied to a C18 reverse-phase HPLC column (VYDAC, Hesperia, 
CA) preeqttilibrated with 0.1% TFA. The bound material was ehted 
at a flow rate of 0.8 ml/min by a linear gradient of 79.9% acetoni- 
trile, 20% water, and 0.1% TFA. The absorbance at 210 nm was 
monitored  and fractions  (0.2 ml) were coUected. 
Metabolic Labeling of Meth A  Cells.  Meth A ascites cells were 
collected and suspended in DMEM without methionine containing 
10% dialyzed FCS at a density of 106 cells/ml. Cells were deprived 
of methionine  in this manner  to deplete the internal methionine 
pools for 4 h.  They were then resuspended in fresh methionine- 
free medium  containing  100/~Ci/ral Trans 3sS-Labd (ICN Bio- 
medicals Inc., Costa Mesa, CA) for 1 h and were harvested and 
processed for purification  of hsp70. 
SDS-PAGE and Protein  Blotting.  Proteins were resolved  on SDS- 
PAGE, subjected to electrophoresis, blotted to nitrocellulose, and 
probed with appropriate  antibodies,  as described (10). 
Tumor Rejection Assays.  Mice (6-8-wk-old female) were im- 
munized with hsp70 or PBS twice at weekly intervals and chal- 
lenged by intradermal injections of live tumor cells 1 wk after the 
last immunization  (10). A high  viability of tumor cells (>98%) 
is an important  prerequisite for reproducible  results. 
Results 
Tumor-specific Immunogenicity  of Tumor-derived hsp 70 Prepa- 
rations.  Apparently homogeneous hsp70 preparations from 
the BALB/cJ  Meth A  fibrosarcoma (Fig.  1, a  and  b) were 
obtained as described in Materials  and Methods.  Typically, 
~ol.5 mg hsp70 is obtained from a 40-ml cell pellet  (8  x 
109 ceils).  This  purification  protocol results in  a relatively 
modest recovery compared with  the traditional  method of 
hsp70 purification (19). However, for reasons discussed in the 
next section, the hsp70 purified by the traditional protocol 
does not dicit  immunity.  BALB/cJ mice were immunized 
twice at weekly intervals  with three different doses of purified 
hsp70 and were challenged with  80,000 live Meth  A  cells 
1  wk  after  the  second  immunization.  Kinetics  of tumor 
growth was monitored (Fig. 2). Tumors grew progressively 
in all unimmunized  mice, but there was significant protec- 
tion from tumor growth in hsp70-immunized mice. This effect 
was dose dependent:  two injections of 3 #g hsp70 each did 
Figure  1.  (a) SDS-PAGE fol- 
lowed  by silver  st~i,l,g of  purified 
hsp70 from Meth A cells. The left 
lane shows hsp70 purified as de- 
scribed  in Materials  and Methods. 
The right lane shows the same 
preparations after ATP-agarose 
chromatography. (b) The prepa- 
ration in the left lane of a was 
blotted  on  nitrocellulose and 
probed with the anti-hsp70 mAb 
SPA-820 (StressGen  Biotechnolo- 
gies Corp.). 
not immunize mice against Meth A, whereas two injections 
of 9/~g each conferred complete protection to all vaccinated 
mice. The tumor-protective effect of Meth A hsp70 was seen 
reproducibly in several experiments (Table 1). Protection was 
observed  at  challenges  of up  to  100,000  Meth  A  cells. 
Challenges  larger  than  this have not been tested.  Further- 
more,  the protective effect has been determined  to be long 
lasting in that mice challenged up to 6 wk after the last im- 
munization have been observed to resist a challenge with Meth 
A sarcoma. Longer time intervals between the last immuni- 
zation  and challenge  have not been tested. 
Because hsp70 is a ubiquitous protein present  in normal 
tissues as well as in tumors,  hsp70 preparations  from liver 
and spleen of normal BALB/c mice were tested for immunoge- 
nicity as described above. No protective effect of hsp70 de- 
rived from normal tissues was observed at any of the three 
comparable doses tested (Fig. 2). Immunity elicited by vacci- 
nation with Meth A-derived hsp70 was observed to be tumor 
specific: mice immunized with Meth A hsp70 remained sen- 
sitive  to  challenges  with  antigenicaUy  distinct,  Meth  A- 
induced  BALB/cJ sarcomas  CMS4 and CMS5  (Table 2). 
Immunogenicity of Tumor-derived hsp  70 Is Sensitive to Exposure 
to ATP.  hsp70 preparations from normal tissues and Meth 
A sarcoma were observed to be antigenically  distinct, as shown 
in Fig. 2. However, proteins of the hsp70 family are highly 
conserved and nonpolymorphic.  It was considered unlikely 
that the hsp70 genes are mutated specifically in tumor cells. 
Two members of the hspT0 family have been shown to bind 
peptides (20-23); the possibility that antigenicity is elicited, 
not by hspT0 per se but by the peptides chaperoned by it, 
was considered.  The presence of HSP-bound peptides has been 
shown in gp96 by acid treatment of purified gp96 (14). How- 
ever,  Flynn et al.  (22,  23) have demonstrated  that  binding 
of peptides by members of the hsp70 family is sensitive to 
ATP. We used this gentle, nondenaturating  method to elute 
peptides from the immunogenic hspT0 preparation.  Purified 
Meth A  hsp70 was applied to an ATP-agarose column and 
was eluted by ATP, as described in the legend to Fig. 1. The 
ATP-duted preparation  (Fig.  1 a, right lane) was applied to 
a Centricon 10 filtration system to remove the peptides and 
ATP. The retentate was analyzed by SDS-PAGE and appeared 
indistinguishable  from the pre-ATP-exposed preparation,  both 
in quantity and apparent homogeneity (Fig.  1 a, right lane). 
The ATP-duted preparation was used to vaccinate mice, as 
described. Mice vaccinated with Meth A-derived hsp70 be- 
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Figure 2.  Mice  were  immunized 
with 9, 6, or 3/~g hsp70 derived 
from  Meth  A sarcoma  (Fig. 1 a, left 
lane) or normal liver and spleen of 
BALB/cJ  mice,  as indicated.  Immu- 
nization was carried out in 200-/~1 
volume subcutaneously  twice at a 
weekly interval. Mice were chal- 
lenged  with 80,000 Meth  A cells  in- 
tradermaUy 1 wk after the second 
immunization.  Each  line  represents 
the kinetics of tumor growth in a 
single mouse. 
fore exposure to ATP (Fig.  1 a, left lane) were significantly 
protected against tumor challenge, but the mice vaccinated 
with the ATP-eluted Meth A hsp70 (Fig. 1 a, right lane) were 
not (Fig. 3).  It was noted in an earlier section that in order 
to isolate immunologically active preparations of hsp70, it 
should be purified by the method described by us, which does 
not use ATP-agarose chromatography, and not with the tradi- 
tional method, which does. The experiments shown in Fig. 
3 form the basis  of that suggestion. 
The low-molecular weight material eluted from hsp70 by 
treatment with ATP was applied to a C18 reverse-phase column 
and eluted by an acetonitrile gradient. A number of distinct 
peaks absorbing at 210 nm were observed (Fig. 4 a, solid line). 
When the same hsp70 preparation was exposed to 350 mM 
NaC1 and the resulting low-molecular weight fraction ana- 
lyzed, a distinctly different and much simpler pattern of peaks 
was observed (Fig. 4 a, dotted line). A salt concentration >350 
mM was not used so as not to denature the hsp70 prepara- 
tion. To demonstrate that the ATP-eluted peaks truly repre- 
sent peptides and that the peptides are derived from cellular 
proteins, Meth A cells were metabolically  labeled for I h with 
[3SS]methionine, as described in Materials and Methods, and 
hsp70 preparations obtained. The low-molecular weight frac- 
tion was derived by Centricon 10 centrifugation, resolved 
on a C18 reverse-phase column, and fractions collected and 
counted. A  number of distinct 3sS-labeled peaks  were ob- 
A  B  C 
20  20  20 
,o  'i 
Of  ,  ,  ,  Of--~ 
0  10  20  30  0  I  0  20  30  0  I  30 
Days post tumor challenge 
Figure  3.  hsp70 purified through an ATP-agarose 
column  loses  its immunogenicity.  Mice  were (a) not im- 
munized  or (b) immunized  with Meth  A-derived  hsp70 
purified  by conventional  chromatography  (Fig. 1 a,/eft 
lane), or (c) immunized  with Meth A-derived hsp70 
purified  by ATP-aflinity  chromatography  (Fig. I a, right 
lane). Mice  were  immunized  and challenged  as described 
in legend to Fig. 2. 
1393  Udono  and Srivastava Table  1.  Immunogenicity of Different Doses of Meth A-derived 
hsp70 against Challenge with Various Numbers of Meth A  Cells 
Frequency of tumor take in: 
Mice immunized 
with Hsp 70 
No.  of Meth  A  cells 
used for challenge  Naive mice  9/zg  6 #g  3/~g 
Exp. 
1  x  10 s  1  5/5  1/5  3/5  4/5 
8  X  10  4  1  4/5  2/5  2/5  1/5 
2  5/5  0/5  ND  ND 
3  5/5  0/5  2/5  5/5 
4  5/5  3/10  3/5  ND 
5  ￿  104  1  4/5  1/5  2/5  4/5 
2  4/5  ND  2/5  ND 
Table  2.  Specificity  of Immunity Elicited by Immunization with 
hsp70 Derived from Meth A  Sarcoma 
No.  of tumor  Tumor used for challenge* 
cells used for 
Mice  challenge  Meth A  CMS5  CMS4 
Naive mice  5  x  104  5/5*  4/5  ND 
1  x  10  s  5/5  5/5  5/5 
Mice immunized 
with Meth A  5  ￿  104  0/5  5/5  ND 
hsp70S  1  x  10  s  0/5  5/5  5/5 
* Tumor cells were injected intradermaUy in 0.2-ml volume. 
* Number  of mice in which  the tumors  grew/total number  of mice 
challenged. 
$ Mice that had been immunized with 9 or 6/~g Meth A hsp70 and had 
resisted a Meth A challenge (from Table 1) were rechallenged with each 
of the three tumors Meth A, CMS4, and CMSS, 2 wk after complete 
regression of the initial challenge. 
tained, indicating that the radioactivity indeed represents pep- 
tides derived from newly synthesized cellular proteins (Fig. 
4 b). Preliminary mass analysis of these peptides by tandem 
mass spectroscopy indicates that they constitute a heteroge- 
neous group ranging in molecular mass from 1,000 to 5,000 
daltons,  the bulk of the peptides being between 1,600 and 
3,200 daltons (Hunt, D.,  personal communication). 
Discussion 
Our observations  suggest that immunogenicity of Meth 
A hsp70 derives from the antigenic peptides chaperoned by 
it. The peptides are derived from cellular proteins by proteo- 
lytic degradation, presumably during antigen processing for 
presentation by MHC class I and dass II proteins. Our ability 
to detect a number of radioactive  hsp70-associated  peptide 
peaks from cells metabolically pulsed for only 1 h (Fig.  4 
b) indicates that this time period is enough for newly synthe- 
sized proteins to be processed and for the resulting peptides 
to associate with hsp70. The repertoire of peptides generated 
in tumor cells must differ from those generated in normal 
tissues because of the tumor-associated mutations, hence the 
difference in  antigenicity of tumor-versus normal tissue- 
derived hsp70 (16). The hsp70 preparations are recognized 
by antigroup-hsp70 antibody N27F3-4 (StressGen; Fig. 1 b). 
Clearly, there are a number of different species of hsp70 (24). 
We have not yet determined if the peptide-binding activity 
detected by us belongs to only a subset or all of the various 
hsp70 species. However,  the endoplasmic reticular hspT0, 
grp78 immunoglobulin binding protein (BiP), is not present 
in our preparations; it is easily distinguished from the cyto- 
solic hsp70 on SDS-PAGE by its size. 
The mechanism whereby the HSP-peptide complexes elicit 
a cellular immune response is not dear. The tumor immu- 
nity elicited by immunization with gp96 HSP is mediated 
by CD8 + T lymphocytes (our unpublished observations).  It 
is possible that hsp70-peptide complexes also elicit immu- 
nity in a similar manner. A class I-restricted response usually 
requires  presentation of antigens through the endogenous 
pathway; it would appear that the HSP-peptide complexes, 
even though provided exogenously,  are able to channel the 
peptides into the class I presentation pathway.  A clue into 
this mechanism may emerge from the observation that deple- 
tion/functional  inactivation  of  macrophages  completely 
abrogates the tumor-specific immunogenicity  of gp96; in con- 
trast, immunization with whole tumor cells is not sensitive 
to depletion of macrophages (our unpublished observations). 
It is conceivable that macrophages possess receptors for gp96 
and other HSP, allowing them to bind HSP-peptide com- 
plexes, which are then directed to the endogenous presenta- 
tion pathway through  a  compartment distinct  from  the 
lysosomal compartment. The role of macrophages in chan- 
neling exogenous antigens into the endogenous presentation 
pathway has recently been suggested in other systems as well 
(25-28). 
Identification of HSP as chaperones of antigenic peptides 
may have a direct beating on immunotherapy  of human cancer. 
One  of  the  major  conceptual  difficulties  in  cancer  im- 
munotherapy has been the possibility that human cancers, 
like cancers of experimental animals,  are antigenically dis- 
tinct (29-31).  The prospect of identifying immunogenic an- 
tigens of individual tumors from cancer patients is daunting 
to the extent of being impractical. The observation that HSP 
chaperone antigenic peptides of the cells from which they 
are derived may circumvent this extraordinary hurdle to specific 
immunotherapy of human cancer. Furthermore, immuniza- 
tion with a biochemically defined pure protein preparation 
may avoid some of the significant risks associated with other 
methods of vaccination such as whole-cell vaccination,  e.g., 
inoculation of patients with immunosuppressive  factors (32- 
34),  transforming DNA,  or infectious viruses. 
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Figure  4.  Peptides  associated 
with hsp70 preparations. (a) hsp70 
was purified from Meth A cells as 
￿9  described in Materials and Methods 
￿9 8o  "~  and was incubated with 350 mM 
"E  NaC1 (dotted line) or 10 mM ATP 
o  and  3  mM  MgC12 (solid line) at 
~o  room temperature for 30 min. The 
<  preparations  were  centrifuged 
￿9  40  through  Centricon  10  and  the 
eluates  applied to  a  C18  reverse- 
phase  column  as  described  in 
Materials and Methods. The x-axis 
represents  elution  time  and  the 
- 20  },-axis represents  the absorbance at 
210 nm. A number of specific peaks 
are observed to elute from hsp70 by 
exposure to ATE (b) Same as in a, 
0  except that hsp70 was prepared from 
metabolically 3sS-labeled Meth A 
cells. The radioactivity peaks rep- 
resent peptides. 
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